Benzinga | May 6, 2021 07:22AM EDT

Barclays Upgrades Neurocrine Biosciences to Overweight, Announces $110 Price Target

Barclays analyst Carter Gould upgrades Neurocrine Biosciences (NASDAQ:NBIX) from Equal-Weight to Overweight and announces $110 price target.